$IIPR
INNOVATIVE INDUSTRIAL PROPERTIES INC

2018 Q4 Form 10-K Financial Statement

#000114420419013981 Filed on March 14, 2019

View on sec.gov

Income Statement

Concept 2018 Q4 2017 Q4 2017
Revenue $4.780M $2.280M $6.420M
YoY Change 109.65% 612.5% 2040.0%
Cost Of Revenue $80.00K $50.00K $100.0K
YoY Change 60.0% 0.0%
Gross Profit $4.700M $2.230M $6.300M
YoY Change 110.76% 3050.0%
Gross Profit Margin 98.33% 97.81% 98.13%
Selling, General & Admin $1.980M $1.290M $5.500M
YoY Change 53.49% 104.76% 587.5%
% of Gross Profit 42.13% 57.85% 87.3%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $900.0K $300.0K $915.0K
YoY Change 200.0%
% of Gross Profit 19.15% 13.45% 14.52%
Operating Expenses $2.900M $1.660M $6.643M
YoY Change 74.7% -63.19% 638.11%
Operating Profit $1.800M $570.0K -$223.0K
YoY Change 215.79% -68.14%
Interest Expense $860.0K $30.00K $200.0K
YoY Change 2766.67%
% of Operating Profit 47.78% 5.26%
Other Income/Expense, Net
YoY Change
Pretax Income $2.670M $610.0K -$100.0K
YoY Change 337.7% -114.56% -97.73%
Income Tax
% Of Pretax Income
Net Earnings $2.670M $610.0K -$72.00K
YoY Change 337.7% -114.56% -98.36%
Net Earnings / Revenue 55.86% 26.75% -1.12%
Basic Earnings Per Share -$0.13
Diluted Earnings Per Share $279.9K $179.9K -$0.13
COMMON SHARES
Basic Shares Outstanding 9.776M shares 3.375M
Diluted Shares Outstanding 3.375M

Balance Sheet

Concept 2018 Q4 2017 Q4 2017
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.10M $11.80M $11.80M
YoY Change 11.02% -64.24% -64.24%
Cash & Equivalents $13.05M $11.76M $11.80M
Short-Term Investments
Other Short-Term Assets $600.0K $500.0K $500.0K
YoY Change 20.0% 66.67% 66.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $13.70M $12.30M $12.30M
YoY Change 11.38% -63.06% -63.06%
LONG-TERM ASSETS
Property, Plant & Equipment $147.4M $67.80M $67.80M
YoY Change 117.4% 126.0% 126.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $120.4M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $267.8M $67.73M $67.70M
YoY Change 295.35% 125.56% 125.67%
TOTAL ASSETS
Total Short-Term Assets $13.70M $12.30M $12.30M
Total Long-Term Assets $267.8M $67.73M $67.70M
Total Assets $281.5M $80.03M $80.00M
YoY Change 251.71% 26.37% 26.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.000M $1.100M $1.100M
YoY Change 81.82% 1000.0% 1000.0%
Accrued Expenses $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $17.20M $6.500M $6.500M
YoY Change 164.62% 124.14% 124.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $17.20M $6.500M $6.500M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $17.17M $6.479M $6.500M
YoY Change 165.07% 124.34% 124.14%
SHAREHOLDERS EQUITY
Retained Earnings $0.00 -$4.464M
YoY Change -100.0% 1.64%
Common Stock $260.6M $64.00M
YoY Change 307.08% -1.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $264.3M $73.55M $73.50M
YoY Change
Total Liabilities & Shareholders Equity $281.5M $80.03M $80.00M
YoY Change 251.71% 26.37% 26.38%

Cashflow Statement

Concept 2018 Q4 2017 Q4 2017
OPERATING ACTIVITIES
Net Income $2.670M $610.0K -$72.00K
YoY Change 337.7% -114.56% -98.36%
Depreciation, Depletion And Amortization $900.0K $300.0K $915.0K
YoY Change 200.0%
Cash From Operating Activities $6.100M $3.500M $5.015M
YoY Change 74.29% 105.88% 195.0%
INVESTING ACTIVITIES
Capital Expenditures -$41.50M -$27.40M -$38.60M
YoY Change 51.46% -8.67% 28.67%
Acquisitions
YoY Change
Other Investing Activities -$115.8M
YoY Change
Cash From Investing Activities -$157.4M -$27.40M -$38.65M
YoY Change 474.45% -8.67% 28.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 111.2M 13.50M 12.39M
YoY Change 723.7% -77.98% -79.8%
NET CHANGE
Cash From Operating Activities 6.100M 3.500M 5.015M
Cash From Investing Activities -157.4M -27.40M -38.65M
Cash From Financing Activities 111.2M 13.50M 12.39M
Net Change In Cash -40.10M -10.40M -21.25M
YoY Change 285.58% -131.52% -164.38%
FREE CASH FLOW
Cash From Operating Activities $6.100M $3.500M $5.015M
Capital Expenditures -$41.50M -$27.40M -$38.60M
Free Cash Flow $47.60M $30.90M $43.62M
YoY Change 54.05% -2.52% 37.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Land
Land
20475000
CY2017Q4 us-gaap Land
Land
11514000
CY2018Q4 us-gaap Investment Building And Building Improvements
InvestmentBuildingAndBuildingImprovements
109425000
CY2017Q4 us-gaap Investment Building And Building Improvements
InvestmentBuildingAndBuildingImprovements
51315000
CY2018Q4 us-gaap Tenant Improvements
TenantImprovements
14732000
CY2017Q4 us-gaap Tenant Improvements
TenantImprovements
5901000
CY2018Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
6298000
CY2017Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
0
CY2018Q4 us-gaap Real Estate Investment Property At Cost
RealEstateInvestmentPropertyAtCost
150930000
CY2017Q4 us-gaap Real Estate Investment Property At Cost
RealEstateInvestmentPropertyAtCost
68730000
CY2018Q4 us-gaap Real Estate Investment Property Accumulated Depreciation
RealEstateInvestmentPropertyAccumulatedDepreciation
3571000
CY2017Q4 us-gaap Real Estate Investment Property Accumulated Depreciation
RealEstateInvestmentPropertyAccumulatedDepreciation
942000
CY2018Q4 us-gaap Real Estate Investment Property Net
RealEstateInvestmentPropertyNet
147359000
CY2017Q4 us-gaap Real Estate Investment Property Net
RealEstateInvestmentPropertyNet
67788000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13050000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11758000
CY2018Q4 us-gaap Short Term Investments
ShortTermInvestments
120443000
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
0
CY2018Q4 us-gaap Assets
Assets
281466000
CY2017Q4 us-gaap Assets
Assets
80028000
CY2018Q4 iipr Tenant Improvements And Construction Payable
TenantImprovementsAndConstructionPayable
2433000
CY2017Q4 iipr Tenant Improvements And Construction Payable
TenantImprovementsAndConstructionPayable
20000
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
1968000
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
1062000
CY2018Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
3759000
CY2017Q4 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
1198000
CY2018Q4 iipr Offering Costs Liability
OfferingCostsLiability
0
CY2017Q4 iipr Offering Costs Liability
OfferingCostsLiability
41000
CY2018Q4 iipr Rents Received In Advance And Tenant Security Deposit
RentsReceivedInAdvanceAndTenantSecurityDeposit
9014000
CY2017Q4 iipr Rents Received In Advance And Tenant Security Deposit
RentsReceivedInAdvanceAndTenantSecurityDeposit
4158000
CY2018Q4 us-gaap Liabilities
Liabilities
17174000
CY2017Q4 us-gaap Liabilities
Liabilities
6479000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
14009000
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
14009000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
250273000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
64000000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
0
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4464000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
264292000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
73549000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
281466000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
80028000
CY2018 us-gaap Operating Leases Income Statement Lease Revenue
OperatingLeasesIncomeStatementLeaseRevenue
14342000
CY2017 us-gaap Operating Leases Income Statement Lease Revenue
OperatingLeasesIncomeStatementLeaseRevenue
6302000
CY2018 iipr Tenants Reimbursements
TenantsReimbursements
445000
CY2017 iipr Tenants Reimbursements
TenantsReimbursements
118000
CY2018 us-gaap Revenues
Revenues
14787000
CY2017 us-gaap Revenues
Revenues
6420000
CY2018 us-gaap Lease Cost
LeaseCost
445000
CY2017 us-gaap Lease Cost
LeaseCost
118000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6375000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5497000
CY2018 us-gaap Severance Costs1
SeveranceCosts1
0
CY2017 us-gaap Severance Costs1
SeveranceCosts1
113000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2629000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
915000
CY2018 us-gaap Operating Expenses
OperatingExpenses
9449000
CY2017 us-gaap Operating Expenses
OperatingExpenses
6643000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
5338000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-223000
CY2018 us-gaap Interest And Other Income
InterestAndOtherIncome
1647000
CY2017 us-gaap Interest And Other Income
InterestAndOtherIncome
151000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
6985000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-72000
CY2018 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1352000
CY2017 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
323000
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
5633000
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-395000
CY2017 us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
5911000
CY2018 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
184988000
CY2017 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
60439000
CY2017 iipr Stock Issued During Period Value Sale Of Preferred Stock
StockIssuedDuringPeriodValueSaleOfPreferredStock
14009000
CY2017 us-gaap Dividends Preferred Stock
DividendsPreferredStock
323000
CY2017 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
1925000
CY2017 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-298000
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
1719000
CY2018 iipr Stock Issued During Period Value Sale Of Common Stock
StockIssuedDuringPeriodValueSaleOfCommonStock
193223000
CY2018 us-gaap Dividends Preferred Stock
DividendsPreferredStock
1352000
CY2018 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
9188000
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
1465000
CY2018 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-390000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
1465000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
1719000
CY2018 iipr Amortization Of Discounts On Short Term Investments
AmortizationOfDiscountsOnShortTermInvestments
-955000
CY2017 iipr Amortization Of Discounts On Short Term Investments
AmortizationOfDiscountsOnShortTermInvestments
0
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
886000
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
992000
CY2018 us-gaap Increase Decrease In Customer Advances
IncreaseDecreaseInCustomerAdvances
4856000
CY2017 us-gaap Increase Decrease In Customer Advances
IncreaseDecreaseInCustomerAdvances
1616000
CY2018 us-gaap Payments To Acquire Real Estate Held For Investment
PaymentsToAcquireRealEstateHeldForInvestment
57474000
CY2017 us-gaap Payments To Acquire Real Estate Held For Investment
PaymentsToAcquireRealEstateHeldForInvestment
32734000
CY2018 us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
22293000
CY2018 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
65500000
CY2017 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
0
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33003000
CY2018 iipr Accrual For Reimbursements Of Tenant Improvements And Construction Funding
AccrualForReimbursementsOfTenantImprovementsAndConstructionFunding
2433000
CY2017 iipr Accrual For Reimbursements Of Tenant Improvements And Construction Funding
AccrualForReimbursementsOfTenantImprovementsAndConstructionFunding
20000
CY2018Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2018 us-gaap Other Preferred Stock Dividends And Adjustments
OtherPreferredStockDividendsAndAdjustments
178000
CY2017 us-gaap Other Preferred Stock Dividends And Adjustments
OtherPreferredStockDividendsAndAdjustments
59000
CY2018 iipr Net Income Loss Used To Compute Common Stockholders
NetIncomeLossUsedToComputeCommonStockholders
5455000
CY2017 iipr Net Income Loss Used To Compute Common Stockholders
NetIncomeLossUsedToComputeCommonStockholders
-454000
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7138952
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3375284
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7285801
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3375284
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.76
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.75
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
66508
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
17.47
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
115011
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
18.63
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
44308
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
18.47
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
30372
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
18.49
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
106839
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
18.01
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
76732
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
29.72
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
24133
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
18.45
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
12079
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
18.67
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
147359
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
23.98
CY2018Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2200000
CY2018 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M12D
CY2018Q4 us-gaap Other Assets
OtherAssets
614000
CY2017Q4 us-gaap Other Assets
OtherAssets
482000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9775800
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3501147
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9775800
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3501147
CY2017 iipr Reclassification Of Common Stock Value
ReclassificationOfCommonStockValue
0
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
173000
CY2017 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
155000
CY2018 iipr Invoices Accrued For Offering Cost
InvoicesAccruedForOfferingCost
0
CY2017 iipr Invoices Accrued For Offering Cost
InvoicesAccruedForOfferingCost
41000
CY2018 us-gaap Property Plant And Equipment Impairment
PropertyPlantAndEquipmentImpairment
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.25in; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Provision for Impairment.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;On a quarterly basis, we review current activities and changes in the business conditions of all of our properties prior to and subsequent to the end of each quarter to determine the existence of any triggering events or impairment indicators requiring an impairment analysis. If triggering events or impairment indicators are identified, we review an estimate of the future undiscounted cash flows for the properties, including, if necessary, a probability-weighted approach if multiple outcomes are under consideration.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.25in; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Long-lived assets to be held and used are individually evaluated for impairment when conditions exist that may indicate that the carrying amount of a long-lived asset may not be recoverable. The carrying amount of a long-lived asset to be held and used is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Impairment indicators or triggering events for long-lived assets to be held and used are assessed by project and include significant fluctuations in estimated net operating income, occupancy changes, significant near-term lease expirations, current and historical operating and/or cash flow losses, construction costs, estimated completion dates, rental rates, and other market factors. We assess the expected undiscounted cash flows based upon numerous factors, including, but not limited to, construction costs, available market information, current and historical operating results, known trends, current market/economic conditions that may affect the property, and our assumptions about the use of the asset, including, if necessary, a probability-weighted approach if multiple outcomes are under consideration. Upon determination that an impairment has occurred, a write-down is recognized to reduce the carrying amount to its estimated fair value. If an impairment loss is not required to be recognized, the recognition of depreciation is adjusted prospectively, as necessary, to reduce the carrying amount of the real estate to its estimated disposition value over the remaining period that the real estate is expected to be held and used. We may adjust depreciation of properties that are expected to be disposed of or redeveloped prior to the end of their useful lives. As of December 31, 2018, no impairment losses were recognized.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q4 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
14000000
CY2019Q1 iipr Reimbursement Payable For Redevelopment Of Building
ReimbursementPayableForRedevelopmentOfBuilding
4800000
CY2018 us-gaap Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
16792
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
193223000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2018 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
6642000
CY2017 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
1050000
CY2018 us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
1337000
CY2017 us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
0
CY2018 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
390000
CY2017 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
298000
CY2018 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0
CY2017 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
14009000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
15693000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5015000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-199255000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-38645000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
184854000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12385000
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1292000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-21245000
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.25in; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="margin-top: 0pt; line-height: 12pt; margin-bottom: 0pt;;font-weight:bold;display:inline;">Acquisition of Real Estate Properties.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;Our investment in real estate is recorded at historical cost, less accumulated depreciation. Upon acquisition of a property, the tangible and intangible assets acquired and liabilities assumed are initially measured based upon their relative fair values. We estimate the fair value of land by reviewing comparable sales within the same submarket or/or region and the fair value of buildings on an as-if vacant basis. Acquisition costs are capitalized as incurred. All of our acquisitions to date were recorded as asset acquisitions.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2017 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
276000
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.25in; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Concentration of Credit Risk</div>. As of December 31, 2018, we owned eleven properties located in Arizona, Colorado, Illinois, Maryland, Massachusetts, Michigan, Minnesota, New York and Pennsylvania.&#160;&#160;The ability of any of our tenants to honor the terms of its lease is dependent upon the economic, regulatory, competition, natural and social factors affecting the community in which that tenant operates. PharmaCann, LLC leases two properties from us,&#160;one in New York and one&#160;in&#160;Massachusetts, which comprised approximately 39% and 82% of rental revenues for the years ended December 31, 2018 and 2017, respectively. </div>In addition, our tenant Holistic MD (as defined below) comprised approximately<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> 18% and14% of rental revenues for the years ended December 31, 2018 and 2017, respectively. </div>Furthermore, our tenant The Pharm (as defined below) comprised approximately<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"> 16% of rental revenues for the year ended December 31, 2018. At December 31, 2018, one of our properties in New York accounted for 20% of our net real estate held for investment. At December 31, 2017, one of our properties in New York, our property in Maryland and our property in Arizona accounted for 43%, 25% and 22%, respectively, of our net real estate held for investment.</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.25in; margin-right: 0px; background: none;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.25in; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We have deposited cash with a financial institution that is insured by the Federal Deposit Insurance Corporation ("FDIC") up to $250,000.&#160;As of December 31, 2018, we had cash accounts in excess of FDIC insured limits. We have not experienced any losses in such accounts.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.25in; margin-right: 0px;"><div style="color: rgb(0, 0, 0); font-family: 'times new roman', times, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 24px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;;font-weight:bold;display:inline;">Reclassifications</div>. Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.</div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018 dei Document Type
DocumentType
10-K
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Entity Registrant Name
EntityRegistrantName
INNOVATIVE INDUSTRIAL PROPERTIES INC
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001677576
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2018Q2 dei Entity Public Float
EntityPublicFloat
233100000
CY2018 dei Trading Symbol
TradingSymbol
IIPR
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9806194
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2018 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Receivable Current
OperatingLeasesFutureMinimumPaymentsReceivableCurrent
25802000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Receivable In Two Years
OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears
26697000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Receivable In Three Years
OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears
27503000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Receivable In Four Years
OperatingLeasesFutureMinimumPaymentsReceivableInFourYears
27160000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Receivable In Five Years
OperatingLeasesFutureMinimumPaymentsReceivableInFiveYears
28070000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Receivable Thereafter
OperatingLeasesFutureMinimumPaymentsReceivableThereafter
328333000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Receivable
OperatingLeasesFutureMinimumPaymentsReceivable
463565000
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
106839

Files In Submission

Name View Source Status
0001144204-19-013981-index-headers.html Edgar Link pending
0001144204-19-013981-index.html Edgar Link pending
0001144204-19-013981.txt Edgar Link pending
0001144204-19-013981-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
iipr-20181231.xml Edgar Link completed
iipr-20181231.xsd Edgar Link pending
iipr-20181231_cal.xml Edgar Link unprocessable
iipr-20181231_def.xml Edgar Link unprocessable
iipr-20181231_lab.xml Edgar Link unprocessable
iipr-20181231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv515308_10k.htm Edgar Link pending
tv515308_ex10-22.htm Edgar Link pending
tv515308_ex21-1.htm Edgar Link pending
tv515308_ex23-1.htm Edgar Link pending
tv515308_ex31-1.htm Edgar Link pending
tv515308_ex31-2.htm Edgar Link pending
tv515308_ex32-1.htm Edgar Link pending